NMCC Clinical Trials: Recruiting

The listing below of clinical trials in use by New Mexico Cancer Center is primarily intended for medical and radiation oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. Unless otherwise noted, the information below, including Trial Status, Date Opened and Date Updated, is obtained from ClinicalTrials.gov. Complete detailed information including eligibility criteria for each trial is available by clicking the ClinicalTrials.gov link provided in that trial's Description Box.

Please contact us here for trial details: research@nmohc.com

Clinical Trials

 BREAST CANCER STUDIES

MK2870-012: Merck Sharp & Dohme LLC: A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice (TPC) in Participants With Triple-Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) at Surgery. NCT Identifier NCT06393374

MK2870-011: Merck Sharp & Dohme LLC_TROFUSE-011: A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011). 

Stemline Therapeutics, Inc_STML-ELA-0422_Elegant: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence – A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

TROPION_Breast05_D7630C0001: This is a research study looking at new treatment options for women with a specific type of aggressive breast cancer that has come back (locally recurrent) or spread to other parts of the body (metastatic).

TRACY-1_RYZ101-201: RayzeBio, Inc.: Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

SIGNAL-ER 101: Signatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer

LUNG CANCER STUDIES

TROPION-Lung17_D763QC00001: A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)

GS-US-600-6165: Gilead Sciences (LAB85469): Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NPM – 002: Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

PROSTATE CANCER STUDIES

5541-CL-0201: Astellas Pharma Global Development, Inc.: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer. NCT Identifier NCT07005154

FGCL-3246-112_FibroGen Inc.: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

AstraZeneca D9735C00001_VECTRA-01: A Phase III, Multi-centre, Randomised Controlled Study to Evaluate the Efficacy and Safety of AZD2265 (FPI 2265 225Ac PSMA-I&T) Compared With Standard of Care in Patients with PSMA-positive Metastatic Castration resistant Prostate Cancer

Novartis CAAA817A12201 AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer

MISCELLANEOUS STUDIES

BEGIN Boston Gene BGER 001: This is a research study looking at the benefits of advanced genetic testing for people with advanced cancer.